MediciNova (MNOV) Stock Overview
A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MNOV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
MediciNova, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.35 |
| 52 Week High | US$2.55 |
| 52 Week Low | US$1.12 |
| Beta | 0.35 |
| 1 Month Change | 8.00% |
| 3 Month Change | -8.78% |
| 1 Year Change | 11.52% |
| 3 Year Change | -43.04% |
| 5 Year Change | -78.16% |
| Change since IPO | -87.67% |
Recent News & Updates
Recent updates
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
Aug 28
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Apr 19MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Nov 27We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Jul 11Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation
Mar 18We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
Oct 12MediciNova to get US patent for MN-166 to treat brain cancer
Sep 15MediciNova's MN-166 to be part of study to treat Long COVID
Aug 16MediciNova begins study of parenteral formulation of MN-166
Jul 22MediciNova announces extension of BARDA contract for Ibudilast development
Jun 30We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Mar 19MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business
Nov 23MediciNova: The Pain Of A Positive Outlook
Aug 31MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study
Jun 21Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
May 15Shareholder Returns
| MNOV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.9% | -1.0% | -2.7% |
| 1Y | 11.5% | -7.0% | 20.5% |
Return vs Industry: MNOV exceeded the US Biotechs industry which returned -7% over the past year.
Return vs Market: MNOV underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| MNOV volatility | |
|---|---|
| MNOV Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MNOV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MNOV's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 13 | Yuichi Iwaki | medicinova.com |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia.
MediciNova, Inc. Fundamentals Summary
| MNOV fundamental statistics | |
|---|---|
| Market cap | US$70.14m |
| Earnings (TTM) | -US$11.16m |
| Revenue (TTM) | n/a |
Is MNOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNOV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.16m |
| Earnings | -US$11.16m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 14, 2025
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MNOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/04 23:30 |
| End of Day Share Price | 2025/08/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MediciNova, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| David Buck | B. Riley Securities, Inc. |
| Yen Ting Chen | Credit Suisse |